Sulfasalazine use while Breastfeeding
Drugs containing Sulfasalazine: Azulfidine, Sulfazine, Azulfidine EN-tabs
Sulfasalazine Levels and Effects while Breastfeeding
Summary of Use during Lactation
Sulfasalazine and its active metabolite mesalamine are poorly excreted into breastmilk. However, rather high levels of the mesalamine metabolite N-acetyl-5-ASA appear in breastmilk and its effects on breastfed infants are unknown. Another sulfasalazine metabolite, sulfapyridine, also appears in milk and infant serum. Bloody diarrhea has occurred in an infant whose mother was taking sulfasalazine and a few cases of diarrhea have been reported in infants exposed to mesalamine in breastmilk, although the rate is not high. Most experts consider mesalamine derivatives to be safe during breastfeeding. If sulfasalazine is required by the mother, it is not a reason to discontinue breastfeeding, but carefully observe breastfed infants for diarrhea. Other agents that do not contain a sulfonamide are preferred.
Sulfasalazine is a chemical combination of sulfapyridine and mesalamine (5-aminosalicylic acid; 5-ASA) which is considered to be the active component. Sulfapyridine is metabolized to acetylated and glucuronidated metabolites. Mesalamine is metabolized to N-acetyl-5-ASA which is inactive in treating inflammatory bowel disease, but its possible effects on the breastfed infant are unknown.
Maternal Levels. Three women who were taking 500 mg of sulfasalazine 4 times daily had breastmilk samples analysed 1 week postpartum. The times of the samples in relation to the doses were not stated. Sulfasalazine milk levels averaged 2.7 mg/L, total sulfapyridine (including all metabolites) averaged 10.3 mg/L and free sulfapyridine (not including metabolites) was 6.5 mg/L. Mesalamine and its metabolites were not measured.
Twelve patients with inflammatory bowel disease were started on sulfasalazine 3 weeks postpartum and had breastmilk levels taken 2 to 3 weeks later. Of 31 samples in the 12 women, only 5 samples had detectable (>1 mg/L) sulfasalazine levels, ranging from 1.5 to 2.5 mg/L with dosages of 1 or 2 grams of sulfasalazine daily. Eight of the patients had 16 untimed milk levels measured while taking dosages of 1 to 3 grams daily. Milk sulfapyridine levels ranged from 1 to 38 mg/L, with some correlation to dosage. Almost no sulfapyridine metabolites were found in milk.
A woman began taking sulfasalazine 500 mg 4 times daily at 4.5 months postpartum for ulcerative colitis. She provided milk samples on 8 days over the next 2 months. A total of 44 samples were obtained, including 10 on the first day of medication. Other samples were obtained midway between nursing bouts which occurred about ever 4 hours. Sulfasalazine was not found in any of the milk samples. Sulfapyridine appeared in milk 4 hours after the first dose in a concentration of 4.8 mg/L. Over the next 2 weeks, sulfapyridine levels fluctuated in the range of 3.9 to 6.6 mg/L and acetylsulfapyridine levels were in the range of 0.4 to 2 mg/L. Total sulfapyridine plus metabolites were in the range of 3.2 to 13 mg/L with most values between 5 and 8 mg/L. Mesalamine was not detected in breastmilk.
Three women who were taking sulfasalazine 3 grams daily for ulcerative colitis each had a single milk level measured 3 to 4 days postpartum. Sampling time in relation to the dose was not reported. Sulfasalzaine levels ranged from <0.5 mg/L to 1.2 mg/L; sulfapyridine levels ranged from 9 to 16.9 mg/L; acetylsulfapyridine levels ranged from 1.1 to 6.7 mg/L. Mesalamine levels were uniformly 0.02 mg/L and N-acetyl-5ASA levels ranged from 1.2 to 3.4 mg/L.
Eight women were taking sulfasalazine during pregnancy and postpartum in an average dosage of 2.6 grams daily. Milk samples were taken 2 hours after breastfeeding, but times in relation to a dose were not stated. Sulfasalazine was undetectable (<0.5 to 1 mg/L) in all but one milk sample in which it was 4.1 mg/L. Sulfapyridine levels in 7 of the samples ranged from 12 to 60 mg/L.
Infant Levels. The breastfed infant of a mother taking sulfasalazine 500 mg 4 times daily had levels of sulfapyridine plus metabolites measured in urine 3 times during 2.5 months of therapy, beginning at 4.5 months postpartum. Total sulfapyridine plus metabolites ranged from 3 to 4.1 mg/L, with most of the drug appearing as metabolites. No mesalamine was detected in the infant's urine.
A 3-month-old breastfed infant whose mother was taking sulfasalazine 3 grams daily had a sulfapyridine blood level of 5.3 mg/L. The infant's mother was a slow acetylator, but the infant's acetylator status was not determined.
Eight breastfed infants whose mothers were taking sulfasalazine in an average dosage of 2.6 grams daily had serum levels measured once between 2 and 24 weeks of age. Sulfasalazine serum levels were undetectable (<0.5 to 1 mg/L) in 6 infants. In the other 2 infants, sulfasalazine serum levels were 1 and 1.7 mg/L. Sulfapyridine was detectable in 5 infants' serum in levels ranging from 1 to 4.8 mg/L.
Effects in Breastfed Infants
One group of investigators stated that they had 10 years of experience using sulfasalazine during the puerperium with no obvious adverse effects in breastfed infants.
The breastfed infant of a mother taking sulfasalazine 500 mg 4 times daily beginning at 4.5 months postpartum experienced no adverse effects during 2.5 months of nursing.
A 2-month-old breastfed infant whose mother was taking sulfasalazine 3 grams daily had an episode of bloody diarrhea. The bloody diarrhea recurred 2 weeks later and persisted until 3 months of age. The infant had up to 6 bowel movements daily and the stools had a loose consistency and were mixed with fresh blood. A colonoscopy revealed a mild inflammatory process and numerous punctate erosions in the mucosa. The infant had a sulfapyridine blood level of 5.3 mg/L, which may have been enhanced because the infant's mother was a slow acetylator. The bloody diarrhea stopped 48 to 72 hours after the mother stopped taking sulfasalazine. A repeat colonoscopy at 4.5 months of age was normal and no further bloody diarrhea occurred up to 14 months of follow-up. The authors felt that the reaction was likely caused by an allergic reaction to sulfapyridine. The reaction was probably caused by sulfasalazine or one of its metabolites in breastmilk. Both sulfapyridine and mesalamine have been reported to cause diarrhea in breastfed infants.
Eight infants whose mothers were taking sulfasalazine in average dosage of 2.6 grams daily were breastfed. Sulfapyridine was detectable in 5 infant's serum in levels ranging from 1 to 4.8 mg/L. The authors pointed out that these levels were far below those required to displace bilirubin from serum albumin binding sites.
A small controlled study reported only in abstract form found no higher rate of diarrhea in the breastfed infants of mothers taking mesalamine or sulfasalazine than in control infants.
A woman with Crohn's disease used sulfasalazine 4 g/day during pregnancy and postpartum. During breastfeeding (extent not stated) she also received infliximab 5 mg/kg every 8 weeks and prednisone 60 mg/day in a tapering schedule. At 6 months of age, the infant was asymptomatic with regular weight gain.
Possible Effects on Lactation
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
(Rheumatoid Arthritis) Auranofin, Etanercept, Gold Sodium Thiomalate, Hydroxychloroquine, Infliximab, Methotrexate, Penicillamine, Sulfasalazine, (Ulcerative Colitis) Infliximab, Mesalamine, Olsalazine
1. van der Woude CJ, Kolacek S, Dotan I et al. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohn's Colitis. 2010;4:493-510. PMID: 21122553
2. Hassid B, Mahadevan U. The use of biologic therapy in pregnancy: a gastroenterologist's perspective. Curr Opin Rheumatol. 2014;26:347-53. PMID: 24625373
3. Nielsen OH, Maxwell C, Hendel J. IBD medications during pregnancy and lactation. Nat Rev Gastroenterol Hepatol. 2014;11:116-27. PMID: 23897285
4. Azad Khan AK, Truelove SC. Placental and mammary transfer of sulphasalazine. Br Med J. 1979;2:1553. PMID: 43760
5. Jarnerot G, Into-Malberg MB. Sulphasalazine treatment during breast feeding. Scand J Gastroenterol. 1979;14:869-71. PMID: 44005
6. Berlin CM Jr, Yaffe SJ. Disposition of salicylazosulfapyridine (Azulfidine) and metabolites in human breast milk. Dev Pharmacol Ther. 1980;1:31-9. PMID: 6108198
7. Christensen LA, Rasmussen SN, Hansen SH et al. Salazosulfapyridine and metabolites in fetal and maternal body fluids with special reference to 5-aminosalicylic acid. Acta Obstet Gynecol Scand. 1987;66:433-5. PMID: 2892343
8. Esbjorner E, Jarnerot G, Wranne L. Sulphasalazine and sulphapyridine serum levels in children to mothers treated with sulphasalazine during pregnancy and lactation. Acta Paediatr Scand. 1987;76:137-42. PMID: 2882643
9. Branski D, Kerem E, Gross-Kieselstein E et al. Bloody diarrhea--a possible complication of sulfasalazine transferred through human breast milk. J Pediatr Gastroenterol Nutr. 1986;5:316-7. PMID: 2870147
10. Nelis GF. Diarrhoea due to 5-aminosalicylic acid in breast milk. Lancet. 1989;333:383. Letter. PMID: 2563532
11. Follmer W. Uber die anwendung sulfonamiden im wochenbett. Klin Wochenschr. 1941;20:912-3.
12. Moretti ME, Spiczynski Y, Hashemi G et al. Prospective follow-up of infants exposed to 5-aminosalicylic acid containing drugs through maternal milk. J Clin Pharmacol. 1998;38 (Suppl):867. Abstract.
13. Correia LM, Bonilha DQ, Ramos JD et al. Inflammatory bowel disease and pregnancy: report of two cases treated with infliximab and a review of the literature. Eur J Gastroenterol Hepatol. 2010;22:1260-4. PMID: 20671559
CAS Registry Number
- Gastrointestinal Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antirheumatic Agents
- Antibacterial Agents
- Antiinfective Agents
LactMed Record Number
Information from the National Library of Medicine's LactMed Database.
Last Revision Date
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.